$5.37
Exscientia is a biotechnology business based in the US. Exscientia shares (EXAI) are listed on the NASDAQ and all prices are listed in US Dollars. Exscientia employs 483 staff and has a trailing 12-month revenue of around $19.6 million.
Our top picks for where to buy Exscientia Ltd ADR stock
How to buy Exscientia stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EXAI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Exscientia stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Exscientia stock price (NASDAQ: EXAI)
Use our graph to track the performance of EXAI stocks over time.Exscientia shares at a glance
Latest market close | $5.37 |
---|---|
52-week range | $3.86 - $9.12 |
50-day moving average | $5.23 |
200-day moving average | $5.64 |
Wall St. target price | $8.33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.35 |
Is it a good time to buy Exscientia stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exscientia price performance over time
Historical closes compared with the close of $5.37 from 2024-07-23
1 week (2024-07-17) | -0.56% |
---|---|
1 month (2024-06-24) | 2.48% |
3 months (2024-04-24) | 30.02% |
6 months (2024-01-24) | -8.52% |
1 year (2023-07-24) | -29.71% |
---|---|
2 years (2022-07-22) | -48.91% |
3 years (2021-07-23) | 91.44% |
5 years (2019-07-20) | N/A |
Exscientia financials
Revenue TTM | $19.6 million |
---|---|
Gross profit TTM | $10.2 million |
Return on assets TTM | -18.33% |
Return on equity TTM | -33.23% |
Profit margin | 0% |
Book value | $2.62 |
Market Capitalization | $649.6 million |
TTM: trailing 12 months
Exscientia share dividends
We're not expecting Exscientia to pay a dividend over the next 12 months.
Exscientia share price volatility
Over the last 12 months, Exscientia's shares have ranged in value from as little as $3.86 up to $9.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exscientia's is 0.844. This would suggest that Exscientia's shares are less volatile than average (for this exchange).
To put Exscientia's beta into context you can compare it against those of similar companies.
- Schrodinger (SDGR.US): 1.51
- Certara (CERT.US): 1.525
- Recursion Pharmaceuticals (RXRX.US): 0.825
Exscientia overview
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. .
Frequently asked questions
nullWhat percentage of Exscientia is owned by insiders or institutions?
Currently 38.499% of Exscientia shares are held by insiders and 38.654% by institutions. How many people work for Exscientia?
Latest data suggests 483 work at Exscientia. When does the fiscal year end for Exscientia?
Exscientia's fiscal year ends in December. Where is Exscientia based?
Exscientia's address is: The Schrödinger Building, Oxford, United Kingdom, OX4 4GE What is Exscientia's ISIN number?
Exscientia's international securities identification number is: US30223G1022
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question